Stephane Bancel - Sep 15, 2023 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Executive Officer, Director
Signature
/s/ James Dillon, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Sep 15, 2023
Transactions value $
$0
Form type
4
Date filed
9/15/2023, 07:28 PM
Previous filing
Jun 30, 2023
Next filing
Feb 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Other $0 +17.9K +0.33% $0.00 5.43M Sep 15, 2023 Direct F2
holding MRNA Common Stock 9.05M Sep 15, 2023 See Footnote F1
holding MRNA Common Stock 6.56M Sep 15, 2023 See Footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F2 Represents the receipt of shares by the reporting person pursuant to pro rata distributions-in-kind, without consideration, of shares of the company's common stock by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") to the partners of Flagship Fund IV and by its general partner, Flagship Ventures Fund IV General Partner, LLC. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
F3 These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.